Angiopeptin 

Angiopeptin, a cyclic octapeptide analogue of somatostatin, is a weak sst₂/sst₅ receptor partial agonist with IC₅₀ values of 0.26 nM and 6.92 nM, respectively. Angiopeptin is a potent inhibitor of growth hormone release and insulin-like growth factor-1 (IGF-1) production. Angiopeptin inhibits adenylate cyclase or stimulates extracellular acidification. Angiopeptin has the potential for coronary atherosclerosis research^[1][2].

IC50: 0.26 nM (sst2) and 6.92 nM (sst5)^[1][2]

Angiopeptin (0.1 nM- 10 μM; for 1 h) acts as a partial agonist (pEC₅₀=6.57) with a maximum response of 423% at 3 μM on the release of tritium on CHO hsst₂ cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Angiopeptin (20 and 50μg/kg; i.h.) significantly inhibits neointimal formation^[1].
Angiopeptin (20 μg/kg; per day) significantly inhibits coronary artery myointimal proliferation in cardiac allografts by appmximalely 50%^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1098.34

C₅₄H₇₁N₁₁O₁₀S₂

113294-82-9

{Nal}CYWKVCT-NH2

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Lundergan CF, et al. Peptide inhibition of myointimal proliferation by angiopeptin, a somatostatin analogue. J Am Coll Cardiol. 1991;17(6 Suppl B):132B-136B.  [Content Brief]

  [2]. Alderton F, et al. Somatostatin receptor-mediated arachidonic acid mobilization: evidence for partial agonism of synthetic peptides. Br J Pharmacol. 2001;132(3):760-766.  [Content Brief]